Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | TEK | Q02763 | 3/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719663 | 0.85 | KCNJ6 (0.49) | LCKTEKKDR | |
| SCHEMBL14107734 | 0.85 | PIK3CD (0.53) | PIK3CDJAK2JAK1KDM1APDE10A | |
| SCHEMBL4641036 | 0.82 | LCK (0.56) | LCKTEKKDM1ACSF1RKDR | |
| SCHEMBL2852141 | 0.77 | JAK2 (0.56) | PIK3CDJAK2JAK1KDM1APDE10A | |
| SCHEMBL2854538 | 0.77 | KDM4E (0.53) | PIK3CDJAK2JAK1KDM1AGRM5 | |
| SCHEMBL4717424 | 0.77 | MAPK14 (0.38) | PIK3CD | |
| SCHEMBL4718461 | 0.77 | NTRK1 (0.42) | PDE10ARET | |
| SCHEMBL4718624 | 0.76 | KCNJ6 (0.51) | — | |
| SCHEMBL4714414 | 0.75 | CYP3A4 (0.57) | LCKTEKKDR | |
| SCHEMBL2854953 | 0.74 | SMN1; SMN2 (0.50) | PIK3CDJAK2JAK1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | disclosed |
| CN-101198602-A | Saminopyrimidine derivates with tIE2 inhibiting activity | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | CN | disclosed |
| EP-1893605-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006103449-A2 | SAMINOPYRIMIDINE DERIVATES WITH TIE2 INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194552-A1 | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity | TIE1, TEK, FLT1 | LCK 902/4885TEK 2/4885PIK3CD 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.